



## AIUM/QIBA Ultrasound Volume Blood Flow Biomarker

### Summary 7-December-2020

Attendees: Brian F., Oliver K., Paul C., Ted L., Cristel B., Jim Z., Jing G., Jon R., Megan R., Nicole L., Rimon T., Sibó L., Stephen P., Tim H., Todd E., Andy M., Shriram S., Mark L., Michelle R. AIUM Staff: Therese C.

#### Action Items in Red

1. Review of Previous Call Summary (October Summary approved. November BC canceled)
2. Action Items
  - 2.1. Discussion of 2D spectral Doppler in QIBA Phantom – Stephen has not had a chance to work on this particular part. Once the profile is set we will circle back to this. QIBA phantom has been sent to Baylor and the sonographers there are doing some testing and feedback may come back at some point soon.
  - 2.2. Abstracts for Ground Work Studies
  - 2.3. Funding sources to be identified by QIBA leadership
    - 2.3.1. Includes NIH, NIST, etc.
    - 2.3.2. NIST has interest in a “phantom library”
    - 2.3.3. SBIR and STTR mechanisms are being considered. **If you have an idea for an abstract let Brian know.**
    - 2.3.4. About 100-to-250 words is typical.
    - 2.3.5. Deadline is somewhat flexible (originally Aug. 31)
    - 2.3.6. Administrative support could be provided by RSNA
    - 2.3.7. Possible support for proposal development
  - 2.4. Discussed Patenting QIBA Phantom
  - 2.5. Draft profile for BC
3. Summary Presentation for 2020 QIBA Virtual General Meeting Thursday, December 10
  - 3.1. **Change slide on dialysis grafts to include fistulas.**
4. Update on VBF Profile Discussions
  - 4.1. Started working on abbreviations
  - 4.2. Executive Summary had some redundancy but felt it read well.
  - 4.3. **Will check with Nancy about setting up the claims to make sure we can achieve them from a statistical level.**
  - 4.4. Subgroup Discussions

#### 4.4.1. Clinical Rationale and Performance

4.4.1.1. Jon made changes after Michelle and he thinks it reads well now. Jing went along with the changes as well. Consensus made on this section. Nancy will be asked to provide feedback. Discussed fistulas and the volume flow rate.

#### 4.4.2. Quality Assurance and Phantoms

4.4.2.1. Discussed acceptance testing.

4.4.2.2. Being conservative in terms of failure rate of the systems regarding VBF. Periodic testing to compare with phantom is wise. Biomarker profile where you are expecting a certain level of performance. Gather data to see overtime how it is going.

#### 4.4.3. Image Acquisition and Analysis

4.4.3.1. Discussed the checklist.

### 5. Matters Arising

Next BC meeting January 4, 2021.

Next VBF Profile meeting is December 9, 2020